retatrutide: Retatrutide Triple Agonist (GLP-1/GIP/GCG) Retatrutide: A Promising Option for

However, severe or prolonged diarrhea can lead to dehydration and electrolyte imbalances, which require medical attention

Visit our help section

Additionally, for individuals with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, GLP-1 receptor agonists are advised to manage glucose and alleviate heart failure symptoms

That is a reasonable accommodation as long as you keep a consistent weekly interval and discuss the change with your prescriber

Diabetes UK, 2024

CLINICAL TRIAL EVIDENCE FOR DUAL GLP-1/GLUCAGON RAs AND TRIPLE AGONISTS IN MASH Survodutide Survodutide, a weekly dual GLP-1/GCG agonist, was assessed in a phase 2 dose-finding trial (NCT04771273) including 293 individuals with histologically confirmed MASH and fibrosis stages F1-F3 [46]